#14DMedical™ The Future of Lung Health Investor Presentation | September 2022 4DMedical Limited (4DX)#2Disclaimer 4DMedical™ This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Company or 4DMedical). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (Group) and their activities current as of September 2022 unless otherwise stated and the information remains subject to change without notice. This presentation contains general background information and does not purport to be complete. No attempt has been made to independently verify the information contained in this presentation. Not an offer or financial product advice The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly any securities, to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement or recommendation to enter into, any contract whatsoever relating to any securities. This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian Corporations Act 2001 (Cth) (Corporations Act) or other offer document under Australian law or the law of any other jurisdiction. This presentation does not constitute an invitation to apply for or purchase Securities and does not include any application form for Securities. This presentation does not constitute an advertisement for an offer or proposed offer of Securities. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation. The distribution of this presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this presentation may not be distributed or released in the United States. The Securities have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act), or the securities laws of any state or other jurisdiction of the United States. Accordingly, the Securities may not be offered or sold, directly or indirectly, in the United States, unless they have been registered under the U.S. Securities Act (which the Company has no obligation to do or procure) or are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable securities laws of any state or other jurisdiction of the United States. International Offer Restrictions This document does not constitute an offer of new ordinary shares ("New Shares") of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside Australia except to the extent permitted below. Bahamas The information in this document is intended solely for the designated recipient. It is not an offer to the public. No distribution of this information to anyone other than the designated recipient is intended or authorised. If You (or any person for whom You are acquiring the Securities) are in The Bahamas, this document has been given to you on the basis that You (and any such person): (a) are a licensee of the Securities Commission of The Bahamas, the Central Bank of The Bahamas or the Insurance Commission of The Bahamas; or (b) are an "accredited investor" (as defined in the Securities Industry Regulations, 2012 of The Bahamas), are deemed to be a non-resident for Bahamas exchange control purposes, will use funds from a non-Bahamas account to purchase the Securities, and acknowledge that there are restrictions on resales of the Securities in The Bahamas. 4DMedical Limited (ASX:4DX) Investor Presentation | August 2022 2#3Corporate overview 4DMedical is a software company creating a step change in the capacity of physicians to diagnose and manage patients with lung disease via its four-dimensional lung imaging platform - XV TechnologyⓇ • Focused on commercialising our flagship XV Lung Ventilation Analysis software (XV LVASⓇ), which utilises mathematical models and algorithms to convert X-ray images into quantitative scan data. Clinically validated to provide real-time, non-invasive analysis of regional lung motion and airflow analysis. The global respiratory diagnostic market represents - USD $31.3¹ billion per annum opportunity Approximately 378 million respiratory diagnostic tests are performed per annum globally. Existing lung diagnostics are decades out of date, not fit for purpose and ripe for displacement. Initial focus on the U.S. respiratory diagnostic market worth USD $13.7 billion per annum. The Company is well funded to execute on commercialisation strategy • Offering is focused on improving hospital and patient outcomes with limited CAPEX requirements. Globally recognised U.S hospital customers and collaborators 72 Global Patents 4DMedical™ Technology conceived 2005 Incorporation Melbourne 2012 SaaS Model Capital light business model with rapid SaaS deployment - expected > 90% gross margins margin. First mover advantage with a robust IP portfolio and advanced product pipeline present significant entry barriers. Strong balance sheet of AUD $51.1 million as at 30 June 2022 and zero debt. USD $31.3 billion global market opportunity 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 1. Frost and Sullivan Report 2020, USD $31.3 billion global spend annually. 2. Frost and Sullivan Report 2020, 378 million procedures are performed annually 3#4Market opportunity Respiratory diagnostics 4DMedical™#5Market opportunity USD $31.3 billion p.a. global spent on respiratory diagnostics 4DMedical™ Market Opportunity by Country² Country Spend (USD) Procedures US 13,716M 73.5M Others 4,964M 59.8M Computed Tomography (CT) Procedures Expenditure 44.5m Germany 2,678M 20.3M USD $11.9 billion Japan 1,905M 22.8M China 1,851M 101.6M UK 1,351M 8.9M France 1,191M 10.2M X-ray Technology Spain 780M 8.4M Nuclear Medicine Pulmonary Function Tests Italy 681M 8.5M Canada 606M 8.0M South Korea 450M 6.8M Turkey 346M 16.1M Australia 285M 5.3M India 276M 25.3M Procedures 253m Procedures 1.44m Expenditure USD $14.5 billion Expenditure USD $1.6 billion Procedures Expenditure 78.9m USD $3.4 billion Switzerland 197M 1.2M Israel 69M 1.1M These four technologies account for 99% of the 3782 million respiratory diagnostics tests performed annually. 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 1. Frost and Sullivan Report 2020 USD $31.3 billion global spend annually (table) 2. 378 million procedures are performed annually (graphic) 5#6Market opportunity Veterans' health in the United States 4DMedical™ • 3.5 million U.S. troops have been exposed to toxic burn pits since 1991. ⚫ PACT Act is set to appropriate USD $280 billion in additional funding over ten years for affected veterans. • Recognition of the impact of Post-Deployment Respiratory Syndrome and the need for a structured clinical response. 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 • Process for securing contracts with DoD¹ and VA² through NASA's SEWP3 program at a pre-agreed pricing structure of USD $171 per • scan. VA to evaluate "emerging technology using existing x-ray imaging equipment to derive four-dimensional models of lung function" as part of the FY23 appropriations bill.4 1. U.S. Department of Defense 2. Veterans Affairs 3. Solutions for Enterprise-Wide Procurement 4. H.R.8294 -Military Construction, Veterans Affairs, and Related Agencies Appropriations Act | 2023 | House of Representatives, 117th Congress) | 117-402. 6#7Respiratory diagnostics are failing us Spirometry: 1846 CT: 1971 ME SPIROMET 4DMedical Limited (ASX:4DX) Investor Presentation | July 2022 49-50 51-52 1 49-50 51-52 53- X-ray: 1895 4DMedical™ Nuclear Medicine: 1971 7#8Respiratory diagnostics are failing us Spirometry: 1846 1D technology Accurate but insensitive 20% market ME SPIROMET Cost Advantages Spirometry: USD $72; Complete PFT: USD $750 49-50 Functional; Accurate; Zero dose; Non-invasive; Low cost (Spirometry) A 51-52 49-50 51-52 53-4 Limitations ⚫ Insensitive • ⚫ Non-specific Complete PFT expensive and time consuming • Effort dependent (repeatability issues) • Not applicable to all patient cohorts 4DMedical™ X-ray: 1895 2D technology Inexpensive, but tells us very little about airflow 67% market Nuclear Medicine: 1971 3D technology Measures both ventilation and perfusion, but has significant limitations 1% market These four technologies account for 99% of the 382 million respiratory diagnostics test performed per annum globally 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 80#9Respiratory diagnostics are failing us Spirometry: 1846 1D technology Accurate but insensitive 20% market CT: 1971 3D technology Sensitive, but expensive and high radiation dose 11% market EME SPIROMET 4DMedical™ X-ray: 1895 2D technology Inexpensive, but tells us very little about airflow 67% market Cost USD $120 (Average estimated) 71 Advantages 2-dimensional scan; Ubiquitous; Relatively inexpensive; Low radiation dosage (0.1 mSv) n and Limitations ⚫ Measures structure rather than function cant • Limited clinical value •Overlapping anatomy means features can be hidden and be missed • Poor record in screening applications These four technologies account for 99% of the 382 million respiratory diagnostics test performed per annum globally 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 9#10Respiratory diagnostics are failing us Spirometry: 1846 1D technology Accurate but insensitive 20% market CT: 1971 3D technology Sensitive, but expensive and high radiation dose 11% market EME SPIROMET Cost Advantages: 4DMedical™ 108 X-ray: 1895 2D technology Inexpensive, but tells us very little about airflow 67% market USD $525 (Average estimated) 3-dimensional scan (can't miss features); Sensitive; High-resolution detail of images Limitations: • Expensive: 4 times the cost of an X-ray • High radiation dose: 70 times an X-ray ⚫ High rate of false positives (~95% in NLCST vs 3% mortality for surgery) Measures structure rather than function • Very high rate of utilisation based on availability These four technologies account for 99% of the 382 million respiratory diagnostics test performed per annum globally 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 and ant 10#11Respiratory diagnostics are failing us Spirometry: 1846 1D technology Accurate but insensitive 20% market Cost EME SPIROMET 108 VQ Scan: USD $1,503 (Average estimated) Advantages: Perfusion analysis capability; Only modality that can identify ventilation-perfusion mismatch; Importance in treating pulmonary embolism & hypertension 49-50 51-52 Limitations: ⚫ High cost, poor resolution of outputs ⚫ Time consuming (1 hour to complete) 1 49-50 51-52 53- • Use of dual radioactive particulate contrast agents raises toxicity concerns, Expensive testing equipment needed 4DMedical™ X-ray: 1895 2D technology Inexpensive, but tells us very little about airflow 67% market Nuclear Medicine: 1971 3D technology Measures both ventilation and perfusion, but has significant limitations 1% market Complex to administer, requires expert analysis, onerous safety precautions These four technologies account for 99% of the 382 million respiratory diagnostics test performed per annum globally 4DMedical Limited (ASX:4DX) Investor Presentation | July 2022 11#124DMedical™ XV Technology™ Viewing - Coronal: XV Scan Layer - Airways - Vasculature - Ribs XV Scan: Specific Ventilation Less 0.0 0.5 1.0 15 More 2.0 Airways: Tube Diameter Smaller 0.0 3.75 7.5 11.25 Larger 15 Smaller 0.0 For demonstration purposes only. Not yet available for sale in the US. Vasculature: Tube Diameter 2.5 5 7.5 Larger 10 Begin Acquisition Inspiration In Expiration Complete Breath End Acquisition#13Advantages of existing modalities in a single platform 4DMedical™ 4DMedical Scan Details Ventilation Report Ventilation Report-Detailed Result 9724 How to Pad Regan he video. Megional ventiabon vaualizations (through the breath phase R Voudraren ers " Sonde Vorte L 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 Functional insight of spirometry at a regional level Comparable radiation dose to X-ray Improved clinical outcomes Faster, more efficient testing using existing hardware K High-detail resolution of a CT scan $ Competitive pricing below incumbent technologies 13#14Clinical Value Proposition 4DMedical™#15Clinical use case: Silicosis 1 2 Validated assessment of regional lung function Reliable repeatability of findings TV: Tidal Volume VH: Ventilation Heterogeneity VDP: Ventilation Defect Percentage HEALTHY DISEASE Healthy Male, Mid - 30s INITIAL SCAN D TV VH VDP 0.68 42.8 13.0 FOLLOW-UP SCAN (3 months later) 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 36-year-old man with Severe, Progressive Silicosis INITIAL SCAN TV VH 0.50 54.5 VDP 17.3 FOLLOW-UP SCAN (3 months post-treatment) 3 4 TV VH VDP TV VH VDP 0.59 47.3 13.8 0.77 44.5 13.8 4DMedical™ Quantification of regional ventilation defects Effective monitoring of disease and treatment effects 15#16Clinical use case: COPD Age 60 Indications Prior biologics therapeutic for re-current exacerbation of moderate obstructive lung disease. Sex Baseline TV VH Structural CT XV LVAS 0.69L 60.8% Summary. • . • SOB for further investigation. At baseline CT was unremarkable. Placed on biologics for history of exacerbation. Following Tx, there are functional improvements in regional ventilation indices (reduced VH and VDP). Notably, appearance of improved. ventilation, specifically in the dependent areas of the right and left lungs. Corresponding with patient reported improvement in symptoms. Clinical Observations . Improved symptoms demonstrated a clinical correlation with improvements in regional ventilation function. Continued therapy with novel biologics. Functional assessment of regional ventilation assists in tracking response to therapy and management. 5 Months Post-Tx 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 Structural CT XV LVAS TV 0.7L VH VDP 18.1% VDP 4DMedical™ 47.0% 13.4% 16#17Clinical use case: Long COVID Age 52 Indications Long COVID symptoms Sex Chest CT: Acute COVID-19 Infection 140 GKVP 226mA Tat 0.0de 140.0KV 247mA Til: 0 Odg Summary • . Patient hospitalised for COVID-19. During admission chest CT observed peripheral ground-glass and consolidative pulmonary opacities (no XV LVAS® imaging was captured). Following Tx and discharge from hospital, the Pt continued to display symptoms of shortness of breath, cough and dyspnea on exertion. Following physician consultation, a follow-up CT and 4DMedical XV LVASⓇ were prescribed. Clinical Observations . Follow-up CT observed a resolution of the peripheral ground-glass and consolidative pulmonary opacities • XV LVASⓇ highlighted heterogeneity between the left and right lung regional performance Structural CT: Peripheral ground-glass and consolidative pulmonary opacities 3 Months Post-acute COVID-19 Infection 120.0 Tilt 0 0deo 512x512 oom: 127 % Compression 21.Jossless) 99 L-600 17.1mm Siro 128 136 • Additionally, previous areas of ground-glass and consolidative pulmonary opacities displayed under ventilation specific to that region of the lung. 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 Structural CT XV LVAS 4DMedical™ 512:512 Zoom: 127 ossless) 05499 L-600 17#18Commercialisation 4DMedical™#194DMedical™ Commercialisation: Two Pillars Clinical trials 3!! Research partners delivering the body of scientific evidence for clinical use Commercial pilots Physicians gaining familiarity with technology and business case for clinical adoption Who Why . Eminent researchers and • leading medical institutes Diagnostics, treatment efficacy, monitoring, disease progression and more Who • Respiratory specialists, imaging centres, hospitals Why • • Assess holistic regional lung function for patient management - ventilation and perfusion Alternative to nuclear medicine Outcome: Scientific investigation into case applications Publishing manuscripts and presenting research to industry Study design: Full scientific method per researcher Outcome: ⚫Clinical familiarisation • Clinical and business case for technology adoption Pilot design: Tiered per facility & physician interest 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 19#20Commercialisation: Clinical trials Completed Studies COPD Cedar Sinai XV LVAS COPD Johns Hopkins XV LVAS Patient Stages Recruitment Progressing Studies - Imaging Complete Lung Transplant Duke University XV LVAS 4DMedical™ COPD Vanderbilt University CB (Veterans) Vanderbilt University COPD Paediatric CF University of Miami Johns Hopkins XV LVAS XV LVAS Progressing Studies - Imaging in Progress BLVR PH COPD University of Miami Cleveland Clinic XV LVAS VQ Imaging in Progress Imaging Complete Completed Study 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 XV LVAS Oregon Health & Science University XV LVAS Lung Transplant Alfred Hospital Melbourne XV LVAS XV LVAS 20 20#21Commercialisation: Johns Hopkins COPD trial result • Has the capability of assessing regional ventilation defects, which is critical to optimising therapies. • Is a repeatable lung assessment tool in a cohort of COPD patients. • Illustrates distribution of airflow within the lungs, corresponding with COPD severity. Mean Specific Ventilation (a.u.) Ventilation Heterogeneity/ 200 400 009 800 Ventilation Heterogeneity By Disease Severity 1,200 1,000 Inspiration Expiration 1 2 GOLD score 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 Patient 2 Patient 1 0 RIGHT Visit 1 RIGHT LEFT UPPER RIGHT Normalized Specific Ventilation 3 4 Normalized Specific Ventilation 0 Upper MIDDLE Middle Lower LOWER LEFT UPPER RIGHT MIDDLE LOWER Normaland Specific Ventilation Visit 2 Normalized Specific Ventilation 1 2 R 4DMedical™ Upper LEFT Lower Middle LEFT UPPER R L MIDDLE 21 L LOWER#22Commercialisation: Vanderbilt PDRS trial results PDRS is not detectable by Spirometry, X-ray or CT only via surgical biopsy. XV clinical trial outputs displaying ventilation variation • 4DMedical's XV Technology® detects the presence of constrictive bronchiolitis. Quantitative scores identify the differences between Veterans with constrictive bronchiolitis and healthy controls. XV TechnologyⓇ confirmed the diagnosis of CB with <0.001% uncertainty. Ongoing assessment of the Vanderbilt clinical trial data is expected to lead to publication. 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 HEALTHY DISEASE 4DMedical™ XV Technology® confirmed the diagnosis of CB with <0.001% uncertainty. 22 222#23Commercialisation: Australia I-MED Radiology Network Comprehensive care. Uncompromising quality. • • • 4DMedical™ Three-year contract signed with Australia's largest radiology provider I-MED with a 250-site network. Successfully rolled out the Company's XV Technology® across 7 sites spanning 5 states. Release of CT variant to accelerate rollout. Used to assist in diagnosis, the unique capability and low-dosage modality developed is proving particularly useful as a surveillance tool in understanding lung disease. 4DMedical ALHI 4DMedical XVScanner ST DEDICAND LUNG CAN 4DMedical • MRFF provided AUD $28.9 million in funding, with AUD $15.0 million yet to be received. First XV Scanner installed at the Prince of Wales Hospital. 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 23#24Commercialisation: United States of America • THE WHITE HOUSE VA PARTMENT OF VETERANS AFFAI UNITED STATES AMERICA U.S. Department of Veterans Affairs 4DMedical™ • • The PACT Act legislation removes the burden of proof on veterans and provides an additional USD $280 billion to be spent over 10 years. Ensuring veterans get the care they need includes ensuring that they are screened for toxic exposure.1 Streamlined process for securing contracts with the DoD and VA through NASA's SEWP program, including a pre-agreed pricing structure of USD $171 per scan. The VHA FY23 budget is USD $301.4 billion², operating 1,255 healthcare facilities and serving 19.2 million veterans across the United States. Providence St.Joseph Health • Providence St. Joseph, is one of 52 hospitals with 1085 clinics³ in the world-class Providence Healthcare network. XV LVAS® software is used to assist in screening for multiple respiratory conditions, including Chronic Obstructive Pulmonary Disease and long-COVID. 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 1. https://www.whitehouse.gov/briefing-room/statements-releases/2022/08/02/fact-sheet-pact-act-delivers-on-president-bidens-promise-to-americas-veterans/ 2. FY 2023 Budget Submission, 'Budget in Brief: Overview', 2023 Congressional Submission, [page BiB-1] (March 2022) <https://www.va.gov/budget/products.asp> 3. Providence, "About Us, (Website accessed 22/08/2022). < https://www.providence.org/about> 24#25Product pipeline 4DMedical™#26Product pipeline Software Company 4DMedical™ Offering XV LVASⓇ (ventilation) CT:V (ventilation) CT:VQ (ventilation/perfusion) Distribution ↑ 4D Medical X-ray (existing hospital hardware) XV Scanner 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 CT (4DMedical hardware) (existing hospital hardware) 4DMedical™ 26#27Product pipeline: 2-year plan The simplicity of offering (Ventilation or Perfusion) with the flexibility of distribution Offering Fluoroscopy (X-ray) Ventilation XV LVASⓇ Perfusion 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 1 Distribution Computed Tomography (CT) XV Scanner (XVD) CT:V CT:VQ Rapid XV LVASⓇ 2 4 4DMedical™ 3 27 27#28Experienced Team 4DMedical™#29Experienced team Executive team 4DMedical™ Dr ANDREAS FOURAS PhD CEO Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical's core technologies. RACHAEL TENKATEN Chief of Staff Aerospace engineer with experience gained through transformative biomedical, aerospace and defence technology projects. Dr AIDAN JAMISON PhD Senior Vice President Engineering With a PHD in medical imaging and a Masters of Law (IP), Aidan is an accomplished technical expert leading the R&D of the Company's product pipeline. NICHOLE MURRAY Vice President Regulatory Affairs & Quality Assurance Over 20 years of experience in regulatory affairs and quality assurance functions in the pharmaceutical and medical device industries. Dr JASON KIRKNESS PhD Senior Vice President Medical & Clinical Affairs Over 20 years' training and experience in pulmonary physiology and sleep medicine, including faculty position at Johns Hopkins and global industry leaders. BETH PLUNKETT Corporate Counsel Accomplished commercial lawyer with expertise spanning corporate, finance, technology licensing and research collaboration contracts. Dr JON DUSTING PhD Chief Research Officer Demonstrated capabilities in translating ambitious research vision into disruptive biotechnology products, including the MRFF-funded XV Scanner. SIMON GLOVER Chief Finance Officer Experienced ASX-listed MedTech company CFO with significant corporate experience in relation to commercialisation, and a track record of driving revenue growth. 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 29#30Experienced team Board of directors Advisory board 4DMedical™ BRUCE RATHIE Non-Executive Chairman Experienced lawyer, Investment Banker and Company Director; currently Non- Executive Director of PolyNovo Limited (PNV.ASX) and Netlinkz Limited NET.ASX). Dr ANDREAS FOURAS PhD Managing Director and Chief Executive Officer Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical's core technologies. LIL BIANCHI Non-Executive Director; Chair, Audit & Risk Committee Experienced contributor of business transformations for US listed technology companies with a beneficial technology product expertise in Al and SaaS offerings. Dr ROBERT A. FIGLIN MD Non-Executive Director Globally recognised leader in genitourinary and thoracic oncology, as well as Editor of the Kidney Cancer Journal and Spielberg Family Chair in Hematology/Oncology at Cedars Sinai. Dr SAM HUPERT MBBS Advisory Board Member Co-founder and Chief Executive Officer of Pro Medicus Ltd (PME.ASX) which develops and markets health imaging software primarily for radiologists in the U.S., Europe and Australia. JULIAN SUTTON Non-Executive Director Chartered Financial Analyst who began his career as an actuarial analyst in Melbourne before moving into funds management with Schroders and Credit Suisse in London. JOHN LIVINGSTON Non-Executive Director; Chair Remuneration & Nomination Committees Founding partner of ASX listed Integral Diagnostics (IDX.ASX) and an industry leader in the implementation of PACS and RIS in radiological settings. 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 EVONNE COLLIER Non-Executive Director Experienced in board appointments (ASX, private, publicly unlisted) with executive background in marketing, innovation/tech and commercial roles; Graduate of the Australian Institute of Company Directors. Dr RAYMOND CASCIARI MD Advisory Board Member Former Chief Medical Officer at St. Joseph Hospital in Orange, CA with over 40 years' experience in Pulmonary Disease, Internal Medicine and Intensive Care Medicine. Prof BRUCE THOMPSON PhD Advisory Board Member Board Member and Past President of the Thoracic Society of Australia and New Zealand; currently Dean of the School of Health Sciences at the University of Melbourne, and a former Head of Physiology Services at the Alfred Hospital. 30#31Executive Summary 4DMedical™#32Executive Summary • • • Clinically validated technology: richer diagnostic value, safer, lower cost. Significant global market with attractive growth opportunities in the core U.S. market. Top tier relationships: clinical and commercial Massively scalable SaaS business model. Strong pipeline protected by a strong (and growing) IP portfolio. Highly experienced Board of Directors and senior management. 4DMedical Limited (ASX:4DX) Investor Presentation | August 2022 4DMedical™ 32#33APPENDICES 4DMedical™#34Additional XV Case Studies 4DMedical™#35Case Study: Novel Treatment Age 60 Indications Sex Novel treatment for a Severe Progressive Silicosis related Occupational Lung Disease Baseline Summary • . At baseline, there are advanced changes of chronic, complicated silicosis as marked by nodular coalescence and fibrosis in the apical regions bilaterally, leading to progressive massive fibrosis. No significant structural changes are seen after treatment (on CT). Following treatment, there are functional improvements in all inspiratory metrics visible on XV LVAS. Notably, the right apical region with areas of relative underventilation (red shading) has markedly improved to average ventilation (green shading) following treatment. 3 Months Post-WLL Clinical Observations Quantifiable, regional improvements in inspiratory function have been observed following treatment for lung disease, which assists the clinician in monitoring treatment effectiveness. In comparison, serial chest CTs showed no significant change following this treatment TV Structural CT XV LVAS 0.5L TV Structural CT XV LVAS 0.6L 4DMedical™ VH 54.5% VDP 17.3% VH 47.3% VDP 13.5%#36Age Sex Case Study: Assessment of Hiatal Hernia 69 Indications • Past history of COVID-19 • Gastric esophageal reflux disease • Recurrent chest infections Summary • CT imaging indicated a large hiatal hernia. XV LVAS demonstrated a greater functional reduction in ventilation than expected from CT changes. Clinical Observations XV LVAS: Relative reduced ventilation in left lower zone due to mass effect from hernia (non-obstructive atelectasis). Not fully appreciated on CT scan. CT Scan Hiatal Hernia XV LVAS Scan 4DMedical™#37Product pipeline (in detail) 4DMedical™#38OFFERING Product pipeline DISTRIBUTION Fluoroscopy (X-ray) Computed Tomography (CT) Ventilation XV LVASⓇ Perfusion X:VQ • • Ventilation (V) refers to the flow of air into and out of the alveoli. Perfusion (Q) refers to the flow of blood to alveolar capillaries. 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 CT:V 4DMedical™ XV Scanner (XVD) Rapid XV LVASⓇ CT:VQ Rapid VQ 38#39Product pipeline Software Company 4DMedical™ Offering XV LVASⓇ (ventilation) CT:V (ventilation) CT:VQ (ventilation/perfusion) Distribution ↑ 4D Medical X-ray (existing hospital hardware) XV Scanner 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 CT (4DMedical hardware) (existing hospital hardware) 4DMedical™ 39#40Product pipeline: 2-year plan The simplicity of offering (Ventilation or Perfusion) with the flexibility of distribution 4Dimensional Data High resolution Low Dose OFFERING DISTRIBUTION Modality Fluoroscopy (X-ray) Ventilation XV LVAS® Perfusion 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 4DMedical™ Computed Tomography (CT) I 40 40#41• • Product pipeline: 2-year plan The simplicity of offering (Ventilation or Perfusion) with the flexibility of distribution 3Dimensional Data • Highly accessible • Same output as XV LVASⓇ DISTRIBUTION Modality Fluoroscopy (X-ray) OFFERING 4DMedical™ Computed Tomography (CT) I Ventilation XV LVAS® CT:V Perfusion 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 41#42• Product pipeline: 2-year plan The simplicity of offering (Ventilation or Perfusion) with the flexibility of distribution Ventilation and Perfusion • 3Dimensional Data • Highly accessible DISTRIBUTION • No contrast required Modality Fluoroscopy (X-ray) OFFERING 4DMedical™ Computed Tomography (CT) I Ventilation XV LVAS® CT:V Perfusion 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 CT:VQ 42 22#43Product pipeline: 2-year plan The simplicity of offering (Ventilation or Perfusion) with the flexibility of distribution Offering Fluoroscopy (X-ray) Ventilation XV LVASⓇ Perfusion 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 1 Distribution Computed Tomography (CT) XV Scanner (XVD) CT:V CT:VQ 4 2 Rapid XV LVASⓇ 3 4DMedical™ 43#44Product pipeline Stage Research & Development CT:V 4DMedical™ CY2022 CY2023 CY2024 CY2025 CT:VQ XV Scanner Regulatory & Review CT:V CT:VQ XV Scanner Commercialisation XV LVASⓇ CT:V CT:VQ XV Scanner 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 44 44#454DMedical™ The Future of Lung Health Corporate CFO Simon Glover [email protected] Administration Company Secretary Melanie Leydin [email protected] Media Enquiries TCN Julia Maguire [email protected]